Volastra Therapeutics

Volastra Therapeutics is a New York City-based clinical-stage biotechnology company dedicated to developing novel cancer therapies that target chromosomal instability (CIN). CIN is a hallmark of cancer, characterized by errors in chromosome segregation during cell division, leading to genomic abnormalities that fuel cancer growth, spread, and resistance to treatments. Volastra's approach is rooted in the understanding that CIN creates unique vulnerabilities in cancer cells, offering a promising avenue for selective therapeutic targeting.

Volastra leverages its innovative CINtech research strategy, which combines proprietary technology, screening techniques, and computational modeling to identify CIN-specific targets and biomarkers. This enables them to design therapies that selectively kill cancer cells while minimizing harm to normal cells. Their pipeline includes two differentiated KIF18A inhibitors in clinical trials, as well as ongoing research into synthetic lethal and immune activation approaches for targeting CIN. Volastra is actively pursuing partnerships and strategic deals to enhance its capabilities and accelerate the development of its therapies, aiming to improve patient outcomes and quality of life.

Volastra Therapeutics is an equal opportunity employer committed to creating a welcoming and inclusive work environment. While specific details about job flexibility aren't mentioned, the company's focus on attracting "talented and motivated employees" suggests an openness to discussing flexible work arrangements on a case-by-case basis, which can benefit employees seeking work-life balance.

Volastra Therapeutics is a New York City-based clinical stage biotechnology company dedicated to developing innovative cancer therapies that target chromosomal instability (CIN), a key vulnerability of cancer cells. By leveraging their proprietary CINtech research strategy, Volastra aims to identify and develop therapies that specifically target CIN-driven processes, leading to the creation of new treatments for patients with a wide range of difficult-to-treat cancers. Their commitment to cutting-edge science and patient-centric approach drives them to revolutionize cancer treatment by empowering patients to enjoy longer and healthier lives.

Volastra Therapeutics promotes a culture centered around scientific curiosity, integrity, and teamwork. They value employees who are passionate about advancing cutting-edge science and turning breakthroughs into therapies that improve patient outcomes and quality of life. The company emphasizes collaboration, agility, and a commitment to patients, creating an environment where innovation and a diverse set of skills are highly valued.

Volastra Therapeutics is committed to fostering a diverse, equitable, and inclusive workplace. They actively seek out talented and motivated individuals with a wide range of skills and backgrounds to contribute to their mission of revolutionizing cancer treatment. They are an equal opportunity employer and do not discriminate against any employee or applicant based on age, color, disability, gender, national origin, race, religion, sexual orientation, veteran status, or any other protected classification.